» Articles » PMID: 6301369

Ceftriaxone Pharmacokinetics in Newborn Infants

Overview
Specialty Pharmacology
Date 1983 Feb 1
PMID 6301369
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Ceftriaxone pharmacokinetics were determined in 40 newborn infants who were 1 to 45 days of age. Mean peak plasma concentrations of 136 to 173 micrograms/ml were observed at the completion of a 15-min intravenous infusion of 50 mg of ceftriaxone per kg. Mean half-life values were 5.2 to 8.4 h, and mean plasma clearances were 0.7 to 1.8 ml/min. Rectal swab cultures from 14 of 16 infants had either reduced numbers of aerobic and anaerobic bacteria or no growth during therapy. A once-daily dosage schedule is suggested for ceftriaxone therapy in newborn infants.

Citing Articles

Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling.

De Sutter P, Rossignol P, Breens L, Gasthuys E, Vermeulen A Pharmaceutics. 2023; 15(9).

PMID: 37765316 PMC: 10536587. DOI: 10.3390/pharmaceutics15092348.


Ceftriaxone Administration Associated with Lithiasis in Children: Guilty or Not? A Systematic Review.

Louta A, Kanellopoulou A, Alexopoulou Prounia L, Filippas M, Tsami F, Vlachodimitropoulos A J Pers Med. 2023; 13(4).

PMID: 37109057 PMC: 10142585. DOI: 10.3390/jpm13040671.


Safety of ceftriaxone in paediatrics: a systematic review protocol.

Zeng L, Choonara I, Zhang L, Xue S, Chen Z, He M BMJ Open. 2017; 7(8):e016273.

PMID: 28827252 PMC: 5634450. DOI: 10.1136/bmjopen-2017-016273.


Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.

Shafiq N, Malhotra S, Gautam V, Kaur H, Kumar P, Dutta S Indian J Med Res. 2017; 145(3):299-316.

PMID: 28749392 PMC: 5555058. DOI: 10.4103/ijmr.IJMR_723_15.


Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis.

Bartkowska-Sniatkowska A, Jonczyk-Potoczna K, Zielinska M, Rosada-Kurasinska J Ther Clin Risk Manag. 2015; 11:1035-41.

PMID: 26170682 PMC: 4494631. DOI: 10.2147/TCRM.S79419.


References
1.
Greenblatt D . Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med. 1975; 293(14):702-5. DOI: 10.1056/NEJM197510022931406. View

2.
Schaad U, McCracken Jr G, Loock C, Thomas M . Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis. Antimicrob Agents Chemother. 1980; 17(3):406-11. PMC: 283800. DOI: 10.1128/AAC.17.3.406. View

3.
Shelton S, Nelson J, McCracken Jr G . In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins. Antimicrob Agents Chemother. 1980; 18(3):476-9. PMC: 284026. DOI: 10.1128/AAC.18.3.476. View

4.
Schaad U, McCracken Jr G, Loock C, Thomas M . Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. J Infect Dis. 1981; 143(2):156-63. DOI: 10.1093/infdis/143.2.156. View

5.
Del Rio M, McCracken Jr G, Nelson J, Chrane D, Shelton S . Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother. 1982; 22(4):622-7. PMC: 183803. DOI: 10.1128/AAC.22.4.622. View